2020-2027 Analysis and Review Isotretinoin Drugs Market
Isotretinoin Drugs Market By Clinical Application (Dermatology, Cancer and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The isotretinoin drugs market was valued at USD 1,349.3 Mn by 2019. The rising prevalence of skin complications worldwide primarily drives the market growth. Furthermore, effective implementation of the treatment guidelines pertaining to dermatological diseases further accelerates the isotretinoin drugs market growth.
Isotretinoin is popularly known as 13-cis-retinoic acid which received approval for medicinal purposes in 1982. Dermatologists usually rely on prescribing isotretinoin in patients resistant to other medications widely employed to treat skin diseases. Pharmacologists are working diligently to develop its clinical application in the treatment of genital warts and recalcitrant condylomata acuminate of the cervix region. The drug needs to be taken under medical supervision owing to its teratogenicity effects and the possibility of causing 20% to 35% of congenital defects in infants exposed to the drug toxicity.
The major segments related to the isotretinoin drugs market are:
By Clinical Application (2017–2027; US$ Mn)
Dermatology
Cancer
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Dermatology complications are leading the clinical application segment for the isotretinoin drug market. The rising prevalence of acne in the Caucasian population throughout the globe primarily drives the market growth. According to the latest research citings provided by the European Society for Medical Oncology (ESMO), the depletion of ozone layers has accelerated the incidence rate of skin complications in the individuals residing in the sub-tropical climate. According to the latest statistics provided by the National Institute of Health (NIH), it is estimated that 90% of the adolescent global population experiences acne at some point of their lifetime. Cancer will be registering comfortable market growth in the near future owing to the significant rise in the occurrence of squamous cell carcinoma throughout the globe. The constant rise in the clinical trial investigation of isotretinoin for its therapeutic efficacy and safety in the treatment of cutaneous t cell lymphoma will further accentuate the market growth.
Hospital pharmacy is presently spearheading the distribution channel segment for the isotretinoin drug market. The drug is associated with teratogenicity effects, hence accurate drug compounding under the supervision of hospital pharmacists is mandatory in order to avoid the occurrence of a drug overdose. Retail pharmacy is expected to highlight impressive market growth in the developing region primarily due to the provision of cheap generic medicines due to government subsidy on essential medicines and constant rise in the generic drug manufacturing across the globe.
North America is currently reigning the geography segment for the isotretinoin drug market. The rising prevalence of dermatological complications primarily determines the market growth in the region. As per the latest statistics provided by the American Academy of Dermatology (AAD), approximately 40 million people in the United States suffer from acne. Additionally, favorable reimbursement scenario and domicile of key players such as Teva Pharmaceutical Industries Limited, Mylan Pharmaceutical Industries Ltd, F.Hoffmann-La Roche Ltd., etc. further consolidates the market growth in the region. Europe is the second-largest regional segment on account of the rising prevalence of cutaneous t-cell lymphoma in the Caucasian population residing in the region. Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period. Flourishing generic drugs market and effective implementation regarding the treatment guidelines pertaining to the treatment of skin complications determine the isotretinoin drugs market growth in the Asia Pacific region.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |